Webster LR, Markman J, Cone EJ, et al. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgrad Med. 2017;129(1):102–110.
http://dx.doi.org/10.1080/00325481.2017.1268902
In the above article, an incorrect phrase (“phase that excludes subjects who are opioid”) has been inserted into the sentence “Category 2 testing without naltrexone blockade often is combined with Category 3 studies, phase that excludes subjects who are opioid which are usually performed in recreational drug users” in the first paragraph of Section 7.2. The correct sentence should read as follows:
Category 2 testing without naltrexone blockade often is combined with Category 3 studies, which are usually performed in recreational drug users.
Taylor & Francis apologizes for this error.